MedDataX Logo

Accuracy of Blood Glucose Detection by Diabetes Alert Dogs

NCT ID: NCT02126605

Last Updated: 2014-04-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

16 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-07-31

Study Completion Date

2015-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Even though there is growing interest in and use of trained Diabetes Alert Dogs (DADs) as a way to monitor blood glucose in type 1 diabetes (T1D), no scientific studies have confirmed the ability of DADs to accurately detect extreme high and low blood sugar. The current project is the first preliminary investigation into the accuracy of DADs, using scientifically rigorous research methods similar to those required to demonstrate accuracy in blood glucose meters. The primary aim of the project is to test the hypotheses that DADs are accurate at detecting extreme blood sugar levels in adults and children with T1D. The proposed project has several other secondary aims, which include determining: 1) the glycemic thresholds and time course for hypo- and hyperglycemic DAD alerts, 2) the degree to which alert accuracy is consistent across different DADs, and 3) whether or not DAD owners appear to experience better psychosocial status and quality of life compared to other individuals with T1D.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In the proposed project, DAD alerts will be compared to blood glucose (BG) readings from a continuous glucose monitoring (CGM) device, as well as a BG meter. CGM, BG meter, and DAD alert data will be collected over a 4-wk period. CGM devices will be "blinded" so that BG readings will not be shown. This will allow for a direct comparison between objective glucose readings generated by approved BG monitoring devices and DAD alerts. This study will also utilize two methods for measuring DAD alerts: (1) use of the event recorder mechanism of the CGM device, and (2) collection of more detailed and qualitative data on DAD alerts using diaries (Daily DAD Diaries) to collect information concerning the occurrence, timing, and type of DAD alerts.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type I Diabetes Mellitus

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

diabetes alert dogs hypoglycemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The participant must have had type 1 diabetes for at least 1 year and been taking insulin since diagnosis
* The participant must have a DAD placed in their home for a minimum of 6 months.
* Participants must not currently be using a continuous glucose monitor (CGM) in their diabetes management.
* Participants must be capable of performing all tasks involved in the study protocol, including filling out questionnaires and diaries in English.
* Participants must have an internet-connected computer compatible with study software.
* Willingness to avoid consumption of acetaminophen-containing products for the duration of the study.

Exclusion Criteria

* Pregnant women-self reported
* Current use of a CGM
* History of a systemic deep tissue infection with methicillin-resistant staph aureus or Candida albicans
Minimum Eligible Age

6 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Virginia

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Linda Gonder-Frederick

Associate Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Linda Gonder-Frederick, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

University of Virginia

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Virginia Center for Behavioral Medicine Research

Charlottesville, Virginia, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jesse Grabman, B.A.

Role: CONTACT

Phone: 434-924-5316

Email: [email protected]

Jaclyn Shepard, Psy.D.

Role: CONTACT

Phone: 434-924-5314

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jesse Grabman, B.A.

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

17296

Identifier Type: -

Identifier Source: org_study_id